Media headlines about Repligen (NASDAQ:RGEN) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repligen earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.304244030113 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- JP Morgan Starts Coverage On Repligen (RGEN) with $42 Target; 4 … – Hill Country Times (hillcountrytimes.com)
- Analysts Expect Repligen Co. (RGEN) Will Post Quarterly Sales of $41.37 Million (americanbankingnews.com)
- Repligen (RGEN) Earns Overweight Rating from Analysts at J P Morgan Chase & Co (americanbankingnews.com)
- JPMorgan Starts Repligen (RGEN) at Overweight, “The Best Pure Play” – StreetInsider.com (streetinsider.com)
- $0.12 EPS Expected for Repligen Co. (RGEN) This Quarter (americanbankingnews.com)
A number of analysts have recently weighed in on RGEN shares. TheStreet raised Repligen from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Thursday, October 5th. CL King started coverage on Repligen in a research note on Monday, November 13th. They set a “buy” rating and a $41.00 price objective for the company. BidaskClub raised Repligen from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, Jefferies Group reissued a “hold” rating and set a $40.00 price objective on shares of Repligen in a research note on Thursday, September 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $44.29.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company had revenue of $36.58 million during the quarter, compared to analyst estimates of $35.69 million. During the same quarter last year, the firm posted $0.08 earnings per share. The firm’s revenue was up 48.2% on a year-over-year basis. analysts predict that Repligen will post 0.61 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/07/repligen-rgen-earning-somewhat-positive-news-coverage-accern-reports.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.